The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://saadvqhd742248.corpfinwiki.com/9470905/retatrutide_vs_tirzepatide_a_comparative_analysis